{"schema_version":"secwatch.filing_event.v1","accession":"0000010795-25-000019","form_type":"8-K","ticker":"BDX","cik":"0000010795","company_name":"BECTON DICKINSON & CO","filed_at":"2025-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.881757+00:00","generated_at":"2026-05-27T02:20:25.139013+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"BD beats Q1 estimates, announces plan to separate Biosciences and Diagnostic Solutions","bullets":["Q1 revenue $5.2B (+9.8% reported, +3.9% organic); adj. EPS $3.43 (+28.0% YoY); GAAP EPS $1.04.","Company raised FY25 adjusted diluted EPS guidance at midpoint; completed $750M share repurchase.","BD board authorized separation of Biosciences and Diagnostic Solutions; target completion in fiscal 2026.","New BD (post-separation) expected FY24 revenue ~$17.8B; separated business ~$3.4B with ~30% adj. EBITDA margins.","Investor Day (Feb 26, 2025) postponed; company to provide update closer to separation."],"urls":{"canonical":"https://secwatch.observer/filing/0000010795-25-000019","json":"https://secwatch.observer/filing/0000010795-25-000019.json","markdown":"https://secwatch.observer/filing/0000010795-25-000019.md","text":"https://secwatch.observer/filing/0000010795-25-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/10795/000001079525000019/0000010795-25-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/10795/000001079525000019/bdx-20250205.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T02:20:25.139013+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}